Clinical Trials
LIXTE Biotechnology's LB-100 Represents Novel Cancer Treatment Approach Through PP2A Inhibition
LIXTE Biotechnology Holdings is advancing LB-100, a first-in-class PP2A inhibitor designed to enhance existing cancer therapies by making tumors more responsive to chemotherapy and immunotherapy in multiple clinical programs targeting solid tumors with significant unmet medical need.
New Oral Rinse Demonstrates Superior Gingivitis Protection in Saliva Environment
ioRinse Ultra has shown complete elimination of gingivitis-causing bacteria within 30 seconds in saliva-inclusive testing, addressing a critical gap in traditional oral rinse evaluation that could transform daily oral care routines.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.
Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Lantern Pharma Reports Strong Q3 2025 Results with AI-Driven Oncology Pipeline Advances
Lantern Pharma demonstrated significant clinical progress in its AI-driven oncology programs, including successful Phase 1a trial results for LP-184 and regulatory clarity for pediatric CNS cancer development, positioning the company to address multiple high-value cancer markets.
Oragenics Regains NYSE Compliance While Advancing Neurological Therapeutics Pipeline
Oragenics Inc. has regained full NYSE American compliance while making significant progress toward its first clinical trial and expanding its neurological therapeutics pipeline through an AI-driven collaboration with Receptor.AI.
Annovis Bio Advances Alzheimer's Treatment with Phase 3 Trial Progress and Promising Biomarker Data
Annovis Bio reports significant progress in its Phase 3 Alzheimer's trial with full site activation and promising biomarker data showing buntanetap's disease-modifying potential, positioning the company for potential regulatory submission.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
March Biosciences Receives FDA RMAT Designation for CAR-T Therapy Targeting Aggressive T-Cell Lymphoma
The FDA granted RMAT designation to March Biosciences' MB-105 CAR-T therapy for relapsed T-cell lymphoma, potentially accelerating treatment development for patients with limited survival options.
NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Development
NanoViricides has raised $6 million through a registered direct offering and concurrent private placement, providing crucial capital to advance its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.
NanoViricides Receives Regulatory Approval for Phase II MPox Trial in Democratic Republic of Congo
NanoViricides has received regulatory approval to begin Phase II clinical trials for its broad-spectrum antiviral drug NV-387 to treat MPox in the Democratic Republic of Congo, representing a potential breakthrough in antiviral therapy.
Polypill Strategy Shows Promise for Heart Failure Treatment, Improving Outcomes and Medication Adherence
A new study demonstrates that a once-daily combination pill for heart failure patients significantly improves heart function, reduces hospitalizations, and enhances quality of life compared to traditional multi-pill regimens.
PCSK9 Inhibitor Combined with Statin Shows Significant LDL Reduction in Heart Transplant Patients
A clinical trial demonstrates that adding the PCSK9 inhibitor alirocumab to statin therapy reduces LDL cholesterol by more than 50% in heart transplant patients, though it did not prevent the development of cardiac allograft vasculopathy.
Healthy Food Delivery Programs Improve Quality of Life for Heart Failure Patients, Study Finds
A new study shows that providing medically tailored meals or fresh produce alongside dietary counseling significantly improves quality of life for heart failure patients following hospitalization, highlighting the potential of food-based interventions in chronic disease management.
Study Finds Prasugrel May Offer Better Outcomes Than Ticagrelor for Diabetic Patients With Stents
New research presented at the American Heart Association's Scientific Sessions 2025 suggests prasugrel may be more effective than ticagrelor at preventing heart attacks, strokes, bleeding complications and death in diabetic patients who received coronary stents, challenging current interchangeable use of these antiplatelet medications.
Family-Based Program Reduces Blood Pressure by 10 mm Hg in Rural Chinese Communities
A family-focused health intervention in rural China achieved significant blood pressure reductions through community support and lifestyle changes, offering a scalable model for cardiovascular disease prevention in resource-limited areas.
Financial Incentives Double Blood Pressure Medication Use But Fail to Improve Health Outcomes
A new study reveals that while daily cash rewards doubled medication adherence among high blood pressure patients, the improved compliance did not translate to better blood pressure control, highlighting the complexity of long-term behavior change.
Food Delivery and Dietary Counseling Program Shows Promise in Reducing Blood Pressure for Black Adults in Food Deserts
A study presented at the American Heart Association's Scientific Sessions 2025 demonstrates that providing home-delivered groceries and dietary counseling significantly improved blood pressure and cholesterol levels in Black adults living in food deserts, though benefits disappeared when support ended, highlighting the need for sustained interventions to address food access barriers.
American Heart Association Launches National Initiative to Combat Rising Heart Valve Disease Deaths
The American Heart Association has launched a comprehensive Heart Valve Initiative to address the growing mortality from heart valve disease, which affects over 28 million people worldwide and contributes to more than 60,000 annual U.S. deaths through improved diagnosis, treatment protocols, and public awareness.
Tailored Vitamin D Doses Reduce Heart Attack Risk by 52% in Heart Disease Patients
Adults with heart disease who received personalized vitamin D supplementation to achieve optimal blood levels experienced more than half the risk of heart attack compared to those without vitamin D monitoring, according to preliminary research presented at the American Heart Association's Scientific Sessions 2025.
Daily Coffee Consumption Linked to Reduced AFib Recurrence in New Clinical Trial
A new clinical trial reveals that adults with atrial fibrillation who drank one cup of coffee daily were 39% less likely to experience recurrent AFib episodes, challenging conventional medical advice about caffeine avoidance for heart rhythm patients.
Catheter Ablation May Eliminate Need for Blood Thinners in Some AFib Patients, Study Finds
New research suggests successful catheter ablation for atrial fibrillation reduces stroke risk enough that many patients can safely discontinue potent blood thinners in favor of aspirin, potentially reducing bleeding complications while maintaining stroke protection.
Shorter Clot-Prevention Therapy After Stent Placement Proves Effective for AFib Patients
New research shows a one-month course of dual clot-preventing therapy followed by single medication treatment is as effective as year-long dual therapy for preventing stroke, heart attack and death in atrial fibrillation patients with stents, while significantly reducing bleeding complications.
Standard Medical Care Outperforms Minimally Invasive Procedure for High-Risk Atrial Fibrillation Patients
New research presented at the American Heart Association's Scientific Sessions 2025 found that standard medical care, including blood thinners when appropriate, proved more effective than a catheter-based procedure for preventing stroke and other complications in older atrial fibrillation patients at high risk of bleeding and stroke.
Oral Cholesterol Medication Shows Promise as Alternative to Injectable Treatments
A new daily oral medication called enlicitide demonstrated up to 60% reduction in LDL cholesterol in clinical trials, potentially offering a more convenient option for high-risk patients who struggle to reach cholesterol targets with current treatments.
CRISPR Gene-Editing Therapy Shows Promise in Lowering Cholesterol and Triglycerides in Phase 1 Trial
A first-in-human trial of CTX310, a CRISPR-based gene-editing therapy, demonstrated significant reductions in LDL cholesterol and triglycerides with sustained effects, potentially offering a one-time alternative to daily medications for patients with difficult-to-treat lipid disorders.
PCSK9 Inhibitor Shows Significant Cardiovascular Risk Reduction in High-Risk Patients Without Prior Heart Events
The VESALIUS-CV trial demonstrates that evolocumab reduces major cardiovascular events by 25% in patients with atherosclerotic disease or diabetes who haven't had prior heart attacks or strokes, potentially expanding preventive treatment options for millions at risk.
Novel Triple-Receptor Medication Shows Promise for Severe Triglyceride Reduction and Liver Health
A new investigational medication called DR10624 demonstrated significant reductions in triglyceride levels and liver fat in patients with severe hypertriglyceridemia, potentially offering a new treatment approach for a condition with limited current options.
Oncotelic Therapeutics Venture Advances Novel Breast Cancer Treatment to Clinical Trials
Sapu Nano, an Oncotelic Therapeutics venture, has received Australian ethics approval to begin clinical trials for Sapu003, an injectable form of everolimus that could significantly improve breast cancer treatment outcomes by enabling full drug absorption through intravenous delivery.